Skip to main content
. 2024 Aug 19;17:70. doi: 10.1186/s13045-024-01590-1

Table 1.

Patient characteristics of the abn(7) cohort

Baseline patient characteristics All patients, n = 519 Intensively treated patients, n = 415
Sex
 Female 233 (45%) 189 (46%)
 Male 286 (55%) 226 (54%)
Age (years)
 Median (IQR) 59 (47, 69) 55 (44, 64)
AML type
 De novo 404 (78%) 336 (81%)
 Secondary 75 (14%) 47 (11%)
 Therapy-related 39 (7%) 31 (7%)
 Missing data 1 (< 1%) 1 (< 1%)
ELN risk category [3]
 Favorable 11 (2%) 11 (3%)
 Intermediate 31 (6%) 24 (6%)
 Adverse 475 (92%) 378 (91%)
 Missing data 2 (< 1%) 2 (< 1%)
WBC at diagnosis (/nL)
 Median (IQR) 9 (3, 30) 9 (3, 30)
 Missing data 14 (3%) 9 (2%)
Blast count at diagnosis (%)
 Median (IQR) 55 (33, 80) 58 (37, 82)
 Missing data 46 (9%) 31 (7%)
Platelets at diagnosis (/nL)
 Median (IQR) 47 (24, 96) 52 (24, 102)
 Missing data 49 (9%) 43 (10%)
Hemoglobin at diagnosis (g/dL)
 Median (IQR) 8.5 (7.15, 9.7) 8.5 (7.1, 9.9)
 Missing data 108 (21%) 102 (24%)
Intensive treatment
 Yes 415 (80%) 415 (100%)
 No 100 (19%)
 Missing data 4 (1%)
Complete remission
 Yes 268 (52%) 253 (61%)
 No 249 (48%) 160 (39%)
 Missing data 2 (< 1%) 2 (< 1%)
Allo-HSCT
 In CR1 126 (24%) 123 (30%)
 Non-CR1/Salvage 38 (7%) 34 (8%)
 Unknown timepoint 6 (1%) 6 (1%)
 No 301 (58%) 208 (50%)
 Missing data 48 (9%) 44 (11%)
Treatment within trial
 Yes 276 (53%) 275 (66%)
 No 239 (46%) 139 (34%)
 Missing data 4 (1%) 1 (< 1%)

Baseline characteristics of the whole (n = 519) and intensively treated (n = 415) abn(7) patient cohort. Continuous variables are given with a median (interquartile range, IQR), and discrete variables are provided with no. (%). CR1 = first complete remission

Italic values indicate missing data